390
Views
11
CrossRef citations to date
0
Altmetric
Biochemistry & Molecular Biology

LncRNA FOXC2-AS1 protects cardiomyocytes from doxorubicin-induced cardiotoxicity through activation of WNT1-inducible signaling pathway protein-1

, , , , , , & show all
Pages 653-658 | Received 24 Sep 2018, Accepted 08 Nov 2018, Published online: 17 Dec 2018

Figures & data

Figure 1. FOXC2-AS1 and WISP1 mRNA expression were downregulated in mice with Dox-induced cardiotoxicity than in healthy mice.

Data here show the comparisons of FOXC2-AS1 (a) and WISP1 mRNA (b) expression between mice with Dox-induced cardiotoxicity and healthy mice.Notes:*, p < 0.05.

Figure 1. FOXC2-AS1 and WISP1 mRNA expression were downregulated in mice with Dox-induced cardiotoxicity than in healthy mice.Data here show the comparisons of FOXC2-AS1 (a) and WISP1 mRNA (b) expression between mice with Dox-induced cardiotoxicity and healthy mice.Notes:*, p < 0.05.

Figure 2. FOXC2-AS1 and WISP1 mRNA expression were positively correlated in mice with Dox-induced cardiotoxicity but not in healthy mice.

Data here show the Pearson correlation coefficient analyses of the correlation between FOXC2-AS1 and WISP1 mRNA expression in mice with Dox-induced cardiotoxicity (a) and in healthy mice (b).

Figure 2. FOXC2-AS1 and WISP1 mRNA expression were positively correlated in mice with Dox-induced cardiotoxicity but not in healthy mice.Data here show the Pearson correlation coefficient analyses of the correlation between FOXC2-AS1 and WISP1 mRNA expression in mice with Dox-induced cardiotoxicity (a) and in healthy mice (b).

Figure 3. FOXC2-AS1 overexpression increased viability of cardiomyocytes under Dox treatment.

Notes: *, p < 0.05.

Figure 3. FOXC2-AS1 overexpression increased viability of cardiomyocytes under Dox treatment.Notes: *, p < 0.05.

Figure 4. FOXC2-AS1 overexpression is likely an upstream activator of WISP1 in cardiomyocytes.

Data here show the effects of FOXC2-AS1 overexpression on WISP1 protein expression (a) and the effects of WISP1 overexpression on FOXC2-AS1 expression under Dox treatment (10 ng/mL) (b), as well as the effects of FOXC2-AS1 overexpression on WISP1 protein expression with Dox treatment (c).Notes:*, p < 0.05.

Figure 4. FOXC2-AS1 overexpression is likely an upstream activator of WISP1 in cardiomyocytes.Data here show the effects of FOXC2-AS1 overexpression on WISP1 protein expression (a) and the effects of WISP1 overexpression on FOXC2-AS1 expression under Dox treatment (10 ng/mL) (b), as well as the effects of FOXC2-AS1 overexpression on WISP1 protein expression with Dox treatment (c).Notes:*, p < 0.05.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.